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Ethical Considerations for COVID-19 Vaccine Trials
in Correctional Facilities
The first phase 3 coronavirus disease 2019 (COVID-19)
vaccine trials began in July 2020. China, Britain, and the
US have experimental vaccines ready to move into large-
scale human testing. In the US, the Vaccine and Treatment
EvaluationUnits,HIVPreventionTrialsNetwork,AIDSClini-
cal Trials Group, and HIV Vaccine Trials Network have
merged resources into Operation Warp Speed, as each
phase 3 trial is anticipated to enroll 30 000 participants.
RecruitmentforthefirstUStrial involvingtheModernavac-
cine is targeting participants “at high risk of SARS-CoV-2
infection.”1 However, even though 39 of the 50 largest US
outbreaks have occurred in correctional facilities and the
case rate of SARS-CoV-2 infection in prisons (3521 per
100 000) has been 5.5 times higher than the general
population,2,3 onekeysettinginwhichUSinvestigatorswill
notberecruitingparticipantsfortrialsofCOVID-19vaccines
are prisons and jails. This omission is an example of unin-
tended consequences of well-intentioned policies.
History of Research in Prisons
In 1978, the National Commission for the Protection of
HumanSubjectsofBiomedicalandBehavioralResearchin-
stituted a moratorium on research in correctional settings
after decades of unethical studies that had enrolled incar-
cerated individuals into studies that involved testing of
drugs and vaccines.4 At the time, incarcerated individuals
were enrolled without informed consent or any federal
oversightofstudies.Studiesthatviolatedethicalstandards
and were explicitly exploitative of incarcerated individuals
were stopped.5 Subsequently, the commission recom-
mendedthatresearchinvolvingprisonersthatposedmore
thanminimalrisk,wasnotstudyingtheprocessofincarcera-
tion, and did not directly improve the health or well-being
ofindividualprisonersshouldnotbeconducted,unlessthe
reasonsforresearchwerecompelling.Onesalientexample
provided in the report was studies of viral hepatitis, which
was highly prevalent among incarcerated individuals. Be-
causeofitsconcernfortheethicalprincipleofjusticeinclini-
cal research, the commission also indicated that the re-
search would have to satisfy “conditions of equity.”4
In 2006, the Institute of Medicine (IOM) (now the
National Academy of Medicine) revisited the issue at the
behest of the US Department of Health and Human Ser-
vices (DHHS).6 In its report, the IOM suggested up-
dates to improve the ability of incarcerated individuals
to participate in limited clinical studies, particularly those
with minimal risk and interventions with demonstrated
safety and efficacy, including phase 3 clinical trials. De-
spite these recommendations, the restrictions on re-
search in correctional settings have not been changed.
Four categories of research are presently permis-
sible in correctional settings (including randomized clini-
cal trials): (1) minimal risk studies on possible causes,
effects, and processes of incarceration and of criminal be-
havior; (2) minimal risk studies of prisons as institutional
structures or of prisoners as incarcerated persons; (3) re-
search on conditions particularly affecting prisoners as a
class; and (4) research on practices that are intended and
deemed likely to improve the health or well-being of
participants.4 However, cumbersome regulations often
make conducting scientific investigations challenging in
these settings. Currently, federal regulation stipulates that
the DHHS secretary must convene a panel of experts be-
fore such a trial takes place, thereby creating barriers to
conducting clinical research in prisons and jails.
The COVID-19 pandemic provides justification to sup-
port reconsideration of the policy to systematically ex-
clude correctional facilities from vaccine trials. Incarcer-
ated individuals and correctional staff are at high risk for
COVID-19,3 and correctional facilities are ideal settings for
the spread of respiratory infections. Newly incarcerated
individuals and correctional staff frequently enter and exit
facilities, social-distancing measures are difficult or impos-
sible to implement, and most correctional facilities are not
built to handle large-scale outbreaks of respiratory infec-
tion or meet the long-term health care needs of individu-
als with COVID-19. Furthermore, incarcerated individuals
have disproportionately high rates of chronic health con-
ditions such as diabetes, hypertension, and cardiac dis-
ease, which are known risks for adverse COVID-19 out-
comesandmortality.ThedeathratefromCOVID-19among
individuals in state and federal prisons is estimated to be
3 times higher than expected if the age and sex distribu-
tions of the US and prison populations were equal.3
Given these high exposure risks, a vaccine trial for
COVID-19 could meet the criteria of the current DHHS
regulations for “research on conditions particularly af-
fecting prisoners as a class.”7 Any trial participation should
be voluntary, not tied to any conditions of incarceration
or release, and must include informed consent, highlight-
ing the risks and benefits to participation, including the
potential toxicities of the vaccine or lack of preventive ben-
efit and potentially the unique risks in the correctional
health system of obtaining aftercare. All trials must be ap-
proved by an institutional review board (IRB) that has a
prisoner representative, and no trial could include more
than 50% enrollment of incarcerated people to mini-
mize the potential of exploitation. While the history of
clinical trials in US prisons suggests that there is poten-
tial and opportunity for coercion in correctional settings,
research on this issue in the contemporary era is limited.
Qualitative research with incarcerated people participat-
ing in clinical trials suggests that their perception of ben-
efits and risks are no different than nonincarcerated par-
ticipants, with the exception of the perceived benefit of
accessing better health care through trial participation.8
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Any vaccine trials that proceed must acknowledge this poten-
tial for coercion, but arguably prevention and treatment of COVID-19
are similarly constrained in the community setting in the US. While
prisoners still need to be protected from the risk of coercion and
exploitation, respect for prisoners also requires recognition of their
autonomy in decision-making, even with true clinical equipoise.
An ethical position that could be considered is that because of the
epidemiology of this disease, it may be unethical to not provide clini-
cal trial opportunities to these groups.
As COVID-19 vaccine trials have started enrollment, the DHHS
secretary should convene a panel of experts to consider the inclu-
sion of incarcerated people in phase 3 trials and consider the fol-
lowing recommendations:
1. Obtain input from currently and formerly incarcerated individu-
als and those who work in corrections: The IOM report sug-
gested the need for “collaborative responsibility,” whereby in-
carcerated people and correctional staff are involved in the design
of research proposals and setting a research agenda. Vaccine trials
should be person-centered and acknowledge the unique logis-
tics of conducting research in correctional facilities without im-
peding good science or violating research ethics. In the longer-
term, incarcerated people should also be part of revising
regulations of clinical research in correctional facilities.
2. Make racial equity a guiding lens: COVID-19 and incarceration dis-
proportionately affect Black communities. One in 3 Black men will
interface with the US prison system in their lifetime (this does not
account for time in jail),9 making vaccine trial data from prisons
and jails likely generalizable to the general population of Black men.
Recruitment for vaccine trials in prisons and jails may improve par-
ticipation of racial and ethnic minorities, thereby improving exter-
nal validity of COVID-19 vaccine trials, which, as of yet, have dis-
proportionately recruited White participants. Clinical trials con-
ducted in the community should obtain permission to follow trial
participants into correctional settings, as necessary, to help mini-
mize loss to follow-up among minority participants.10
3. Learn from history: The urgency of the current pandemic and of
past and future respiratory pandemics may lead to the desire for
quick, easier solutions. The present sense of urgency to find a vac-
cine makes it difficult to take time to support inclusive decision-
making and consider long-term consequences. The need for quick
results may minimize the interests of vulnerable populations.
4. Ensure receipt of efficacious vaccines and care after the trial con-
cludes:Manycorrectionalsettingsarenotwellequippedtodealwith
screening for and treating COVID-19, much less aftercare following
vaccine trials. Inclusion of incarcerated individuals in clinical trials
must also include resources for correctional health systems to at-
tend to vaccine complications and, once the trials conclude, univer-
sal access to these vaccines.9 Funding for aftercare, like any com-
munity setting, should be guaranteed by the study sponsor and uni-
versal access to vaccines proven to be effective and safe should be
guaranteed by federal legislation, as there currently is no mandate
to provide vaccines to those who are incarcerated.
5. Convene a federal oversight board: Aside from the specific IRB
processes outlined in the current regulations, a federal over-
sight board should be convened that monitors all COVID-19 vac-
cine trials conducted in correctional settings, regardless of
whether the trials are funded by the federal government.
6. Study implementation of vaccines in correctional systems: Imple-
menting clinical trials in correctional facilities, especially in prisons
where sentence lengths are typically longer than a year, could help
toenablehighlevelsofadherenceandfollow-up, includingantibody
testing. However, once efficacious and safe COVID-19 vaccines are
developed, additional research will be needed to determine how
best to administer and improve uptake of vaccines in correctional
systems. InjailswheretheriskforCOVID-19isstillhighbutthepopu-
lation throughput is much higher, effective strategies for follow-up
within the facility and after release must be identified.
Conclusions
Incarcerated people and correctional staff are at high risk of con-
tracting COVID-19. Federal regulations, formed in reaction to previ-
ous unethical experimentation, were established to protect incar-
cerated populations from future mistreatment. However, jails and
prisons have become an epicenter of the current pandemic. With
appropriate cautions and a person-centered approach, the US re-
search community should revisit whether COVID-19 vaccine trials
should include incarcerated individuals and correctional facility staff.
Correctional settings present the opportunity to determine vac-
cine efficacy when trials are ethically conducted and perhaps to the
benefit of the health of people who live and work there. Not revis-
iting the inclusion of these groups in COVID-19 clinical trials pre-
sents another set of ethical challenges.
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